Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1992-09-09
1995-07-25
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514403, 514404, A61K 31425, A61K 31415
Patent
active
054362580
ABSTRACT:
The administration of a xanthine oxidase inhibitor is effective for the treatment or prevention of the excessive resorption of bone in conditions such as osteoporosis and the like.
REFERENCES:
patent: 4346094 (1982-08-01), Beck et al.
Bax et al., Biochem. Biophys. Res. Commun., 183(3), 1153-1158 (1992).
Chang et al., Ann. Rhem. Dis., 51, 1223-1229 (1992).
Das, Prostaglandins Leukot Essent Fatty-Acids 44(4), 201-210 (1991).
Garrett et al., J. Clin. Invest., 85, 632-639 (1990).
Robinson et al., J. Clin. Invest., 56, 1181-1188 (1975).
Key et al., Bone, 11(2), 115-119 (1990).
Rathakrishnan et al., J. Bone Miner. Res., 7, 1139-1148 (1992).
Tiku et al., J. Immunol., 145, 690-696 (1990).
Zaidi et al., J. Bone Miner. Res., 7 (Suppl):S242 (1992).
Fallon et al., J. Bone Miner Res., 1 (Suppl):1 (1986).
Okabe et al., Bull. Kanagawa Dent. Coll., 18(2), 151-9 (1990).
Blake David R.
Panetta Jill A.
Zaidi Mone
Eli Lilly and Company
Goldberg Jerome D.
Jones Joseph A.
London Hospital Medical College
Sales James J.
LandOfFree
Prevention of bone resorption does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prevention of bone resorption, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prevention of bone resorption will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-739846